FORM Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.7/10
Best for: starting below a standard dose, with microdose tiers
FORM's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
$299/month is the opening rate on compounded semaglutide, $399/month on compounded tirzepatide, with microdose tirzepatide at lower strength going for $199/month; dissolving oral tablets exist as well. Reaching FDA-approved Zepbound or Wegovy means a membership of $95/month instead. Las Vegas is the base for FORM by GBY, which writes through the provider network at Övie Health Group and sells longevity, peptide and hair treatments too. Cancel whenever; nothing binds you long term.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to FORM
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
FORM at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Wegovy® & Zepbound®
- Starting price
- $95/mo (Live-verified product page: "$95 monthly membership" — access/consult fee, medication cost via NovoCare not disclosed...)
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How FORM scores
Six columns, each one computed from something FORM has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
7.1/10$199/month is 25% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on FORM
Last checked August 2026- Re-read the price on file across 7 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with FORM involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1FORM publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3FORM does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $215, tirzepatide $199. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether FORM serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
FORM support, as documented
- hello@formbygby.com
GLP-1 medications FORM offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Live-verified product page: "$299 per month"
Live-verified product page: "$399 per month"
Live-verified product page: "$215 per month"
Live-verified product page: "$299 per month"
Live-verified product page: "$199 per month"
Live-verified product page: "$95 monthly membership" — access/consult fee, medication cost via NovoCare not disclosed on-site
Live-verified product page: "$95 monthly membership" — access/consult fee, medication cost via LillyDirect not disclosed on-site
Check the price yourself before you pay
Every figure here was read off FORM's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide at $199 a month, within the normal band around this register's $267 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What FORM charges
FORM lists $199/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- Compounded semaglutide — $299/month
- Compounded tirzepatide — $399/month
- Compounded semaglutide — $215/month
- Compounded tirzepatide — $299/month
- Compounded tirzepatide — $199/month
- Brand-name semaglutide — $95/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.
What FORM dispenses
FORM prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. Both routes are available: the FDA-approved pen, or a compounded version at lower cost. The distinction is not cosmetic — the approved product has been reviewed for safety, efficacy and manufacturing quality, and a compounded preparation has not.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at FORM at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.
What we could verify
FORM publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- injections are the thing keeping you from starting
Our read
FORM costs more than the middle of this market, and the oral option is the clearest thing that premium buys. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less. Breeze Meds is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
FORM's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay FORM
Starting at $199/month. Check today's price, then book the free consultation.
Where FORM is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this FORM review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See FORM's current pricing
Plans start at $199/month. The free consultation is where you learn whether you qualify, and what it costs today.